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A B S T R A C T
Background
Chronic neutrophilic inflammation, both in the presence and absence of infection, is a feature of bronchiectasis in adults and children.
The anti-inflammatory properties of non-steroid anti-inflammatory drugs (NSAIDs)may be beneficial in reducing airway inflammation
and thus potentially improve lung function and quality of life in patients with bronchiectasis.
Objectives
To evaluate the efficacy of inhaled NSAIDs in the management of non-cystic fibrosis bronchiectasis in children and adults.
Search methods
We searched the Cochrane Airways Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (The
Cochrane Library 2009, issue 3),MEDLINE, OLDMEDLINE and EMBASE databases. The latest searches were carried out inOctober
2009
Selection criteria
All randomised controlled trials comparing inhaled NSAIDs to a control group (placebo or usual treatment) in children or adults with
bronchiectasis not related to cystic fibrosis.
Data collection and analysis
We reviewed the results of the searches against pre-determined criteria for inclusion.
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Main results
One small, short-term trial was eligible for inclusion. We included this study of 25 adults with chronic lung disease (including
bronchiectasis) as the other conditions were linked to development of bronchiectasis and all had chronic sputum production.
The single trial in adults reported a significant reduction in sputum production over 14 days in the treatment group (inhaled in-
domethacin) compared to placebo (difference -75.00 g/day; 95% CI -134.61 to -15.39) and a significant improvement in a dyspnoea
score (difference -1.90; 95% CI -3.15 to -0.65). There was no significant difference between groups in lung function or blood indices.
No adverse events were reported.
Authors’ conclusions
There is currently insufficient evidence to support or refute the use of inhaled NSAIDs in the management of bronchiectasis in adults
or children. One small trial reported a reduction in sputum production and improved dyspnoea in adults with chronic lung disease
who were treated with inhaled indomethacin, indicating that further studies on the efficacy of NSAIDs in treating patients with
bronchiectasis are warranted.
P L A I N L A N G U A G E S U M M A R Y
Inhaled non-steroid anti-inflammatories (NSAIDs) for children and adults with bronchiectasis
The airways of patients with bronchiectasis are characterised by chronic inflammation. The anti-inflammatory effects of inhaled non-
steroid anti-inflammatory drugs (NSAIDs) may be beneficial in patients with bronchiectasis. However, the short and long-term benefits
in both adults and children require investigation, in addition to the potential side effects of the long-term use of NSAIDs. For this
review we found one small study that reported an improvement in sputum production and dyspnoea (shortness of breath) in adults with
chronic lung disease (chronic bronchitis, bronchiectasis or diffuse panbronchiolitis) who received inhaled indomethacin compared to
the placebo group. There was no significant improvement in lung function (forced expiratory volume in one second (FEV1) and vital
capacity (VC)). However, the small scale of this study and the collective analysis of data from the three disease states made it difficult
to draw any solid conclusions on the benefit of using NSAIDs to treat adults with bronchiectasis. There were no studies identified on
the use of NSAIDs in children with bronchiectasis.
B A C K G R O U N D
Description of the condition
Bronchiectasis, previously termed an ’orphan disease’, is increas-
ingly recognised as a major cause of respiratory morbidity, espe-
cially in developing countries (Karadag 2005; Karakoc 2001) and
in pockets of affluent countries (Chang 2008). The underlying ae-
tiology of bronchiectasis varies; it may follow recurrent respiratory
infections or be secondary to rare immune deficiencies. However,
bronchiectasis is also a common pathway for a variety of diseases.
Thus, the presence of bronchiectasis is also increasingly recognised
in common (e.g. chronic obstructive pulmonary disease (COPD)
(O’Brien 2000) and uncommon respiratory diseases (e.g. bronchi-
olitis obliterans and sarcoidosis (Lewis 2002)) as well as non-pri-
mary respiratory (e.g. autoimmune) diseases.When bronchiectasis
is present with another underlying disorder, it increases the mor-
bidity and mortality of the underlying disease (Keistinen 1997;
Lewis 2002). For example, in diseases such as COPD the pres-
ence of bronchiectasis has been reported in 29% to 50% (O’Brien
2000) of cohorts and when present increases the severity and fre-
quency (Gursel 2006) of respiratory exacerbations.
The dominant symptoms and signs of bronchiectasis are pro-
ductive or wet cough, dyspnoea on exertion and presence of
other respiratory signs (clubbing, chest wall deformity, respira-
tory noises such as wheeze or crepitations on auscultation). In the
long term pulmonary decline may occur (Keistinen 1997). Also,
as in patients with COPD, children and adults with bronchiectasis
also suffer from recurrent acute exacerbations, some of which re-
quire hospitalised treatment (Chang 2008). Effectivemanagement
regimes for bronchiectasis improve quality of life (Courtney 2008;
Martinez-Gracia 2005; Muthalithas 2008), and could reduce the
frequency or severity of respiratory exacerbations (Cymbala 2005)
2Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and/or the long-term pulmonary decline (Chang 2008). Thus,
management of the symptoms and severity of bronchiectasis is
important.
Description of the intervention
Non-steroid anti-inflammatory drugs (NSAIDs) are a class of
medication that act as non-selective inhibitors of the enzyme
cyclooxygenase, inhibiting both the cyclooxygenase-1 (COX-1)
and cyclooxygenase-2 (COX-2) isoenzymes. Non-steroidal anti-
inflammatories have analgesic, antipyretic and anti-inflammatory
effects and reduce pain, fever and inflammation. NSAIDs are usu-
ally given orally but the inhaled formulation has been also used
in people with bronchorrhoea, a feature present in many patients
with bronchiectasis (Tamaoki 1992). A Cochrane Review of oral
NSAIDs for people with bronchiectasis did not find any suitable
randomised controlled trials (Kapur 2007).
How the intervention might work
Based on Cole’s ’vicious circle hypothesis’, microbial colonisation/
infection is important in the pathophysiology of bronchiectasis
as it leads to bronchial obstruction and an abnormal or exag-
gerated inflammatory response (Cole 1986). Anti-inflammatory
drugs may reduce the inflammatory cascade and thus ameliorate
symptoms and reduce long-term pulmonary decline.
As the airways of patients with bronchiectasis have intense neu-
trophilic inflammation (Cole 1986), the anti-inflammatory ef-
fect of NSAIDs may have a beneficial effect for patients with
bronchiectasis. “Blockade of cyclooxygenase pathway with in-
domethacin could decrease respiratory tract fluid and mucus by
inhibiting chloride secretion and glandular secretion and by en-
hancing Na absorption across airway mucosa” (Tamaoki 1992).
Animal studies have shown that pre-treatment with inhaled in-
domethacin protects the airway from distilled water and ozone
which increases lung resistance through swelling of airway epithe-
lial cells (Mochizuki 2002).
Why it is important to do this review
Although NSAIDs may have potential benefits for those with
bronchiectasis, oral NSAIDs are associated with a number of ad-
verse events, particularly of the gastrointestinal tract (Behrman
2003). NSAIDs may be better tolerated when inhaled, however
transient upper airway irritation has been reported (Ong 2004;
Sestini 1999). It is therefore important to assess any additional
side affects associated with the inhalation of NSAIDs.
In cystic fibrosis (CF), preliminary evidence suggests that NSAIDs
may prevent pulmonary deterioration in people with mild lung
disease due to CF (Lands 2007). However, extrapolation of treat-
ment for CF to non-CF bronchiectases may be harmful (e.g. re-
combinant human DNase efficacious in CF causes harm in non-
CF bronchiectasis (Crockett 2001)). Thus, a systematic review on
the efficacy of inhaled NSAIDs in the management of children
and adults with bronchiectasis would help guide clinical practice.
O B J E C T I V E S
To evaluate the efficacy of inhaled NSAIDs in children and adults
with bronchiectasis:
(a) during stable bronchiectasis;
and for reducing:
(b) the severity and frequency of acute respiratory exacerbations;
and
(c) long-term pulmonary decline.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) comparing inhaled
NSAIDs to a control group (placebo or usual treatment) in pa-
tients with bronchiectasis
Types of participants
Children or adults with bronchiectasis (defined clinically or radi-
ologically) not related to cystic fibrosis. We excluded participants
with cystic fibrosis or with other diseases where bronchiectasis was
not present.
Types of interventions
All types of inhaled NSAIDs.
Types of outcome measures
Primary outcomes
Weplanned to obtain data on at least one of the following outcome
measures.
(A) For short-term effectiveness (12 months or less):mean dif-
ference in bronchiectasis severity control (quality of life (QOL),
cough scores).
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(B) For medium to long-term outcomes (> 1 year): lung func-
tion data (forced expiratory volume in one second (FEV1) % pre-
dicted).
Secondary outcomes
(A) For short-term effectiveness (12 months or less):
a) total numbers of days with respiratory symptoms;
b) mean difference in lung function indices (spirometry, other
lung volumes, airway hyper-responsiveness);
c) proportions of participants who had respiratory exacerbations
and/or hospitalisations;
d) total number of hospitalised days;
e) mean difference in other objective indices (airway markers of
inflammation, exhaled nitric oxide etc.);
f ) proportions experiencing adverse effects of the intervention (e.g.
gastritis, haematemesis, ecchymoses, etc.);
g) serious adverse events (e.g. haemoptysis, bronchospasm etc.).
(B) For medium to long-term outcomes (> 1 year):
h) radiology scores (high resolution computed tomography scans
or chest radiograph);
i) clinical indices of bronchiectasis severity control (QOL, cough
diary, Likert scale, visual analogue scale, level of interference of
cough, etc.);
j) mortality;
k) proportions experiencing adverse effects of the intervention (e.g.
gastric bleeding, gastritis, haematemesis, cardiac events, etc.);
l) serious adverse events (e.g. haemoptysis, bronchospasm etc.).
Search methods for identification of studies
Electronic searches
We used the following topic search strategy to identify the relevant
randomised controlled trials listed in the electronic databases:
(“bronchiectasis” OR “suppurative lung disease” as (textword)
or (MeSH )) AND (“inhaled” OR “nebulise” OR “nebulised”
as (textword) or (MeSH )) AND (“anti-inflammatory” OR “di-
clofenac” OR “etodolac” OR “ketorolac” OR “sulindac” OR “tol-
mentin” OR “diflunisal” OR “salsalate” OR “meloxicam” OR
“piroxicam”OR“flurbiprofen” OR “Ibupropen”OR “ketoprofen”
OR “naproxen”OR “oxaprozin” OR “indomethacin” OR “COX2
inhibitors” OR “celecoxib” OR “rofecoxib” OR “valdecoxib”) as
(textword) or (MeSH)
We identified trials from the following sources:
1. the Cochrane Airways Group Trials Register;
2. the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2009, issue 3);
3. MEDLINE (1966 to present);
4. OLDMEDLINE (1950 to 1965); and
5. EMBASE (1980 to present).
For MEDLINE, OLDMEDLINE and EMBASE we combined
the topic search strategy with the RCT search filter as outlined in
the Airways Group module.
Searching other resources
We also searched the references in relevant publications. We
planned to communicate with the authors of trials included in the
review, if necessary.
Data collection and analysis
Selection of studies
From the title, abstract or descriptors, two authors (SP, AC) inde-
pendently reviewed the literature searches to identify potentially
relevant trials for full review. We conducted searches of bibliogra-
phies and texts to identify additional studies. From the full text
and using the specified criteria, the same two authors indepen-
dently selected trials for inclusion. We planned to resolve any dis-
agreement by third party adjudication (JU).
Data extraction and management
We reviewed trials that satisfied the inclusion criteria for the fol-
lowing information: study setting; year of study; source of funding;
patient recruitment details (including number of eligible subjects);
inclusion and exclusion criteria; other symptoms; randomisation
and allocation concealment method; numbers of participants ran-
domised; blinding (masking) of participants, care providers and
outcome assessors; dose and type of intervention; duration of ther-
apy; co-interventions; numbers of patients not followed up; rea-
sons for withdrawals from study protocol (clinical, side effects,
refusal and other); details on side effects of therapy; and whether
intention-to-treat analyses were used where possible. We would
have extracted data on the outcomes described previously. Where
required we planned to obtain further information from the au-
thors.
Assessment of risk of bias in included studies
In order to assess the risk of bias, two review authors (SP, AC)
independently assessed the quality of the studies according to the
criteria described by Jüni (Jüni 2001).
Allocation concealment
We assessed allocation concealment as follows.
1. Adequate: if the allocation of participants involved a central
independent unit, on-site locked computer, identically appearing
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numbered drug bottles or containers prepared by an independent
pharmacist or investigator, or sealed opaque envelopes.
2. Unclear: if the method used to conceal the allocation was
not described.
3. Inadequate: if the allocation sequence was known to the
investigators who assigned participants or if the study was quasi-
randomised.
Generation of the allocation sequence
Each study was to be graded for allocation concealment as follows.
1. Adequate: if methods of randomisation included using a
random number table, computer-generated lists or similar
methods.
2. Unclear: if the trial was described as randomised, but no
description of the methods used to allocate participants to
treatment group was described.
3. Inadequate: if methods of randomisation included
alternation, the use of case record numbers, dates of birth or day
of the week, and any procedure that was entirely transparent
before allocation.
Blinding (or masking)
Each study was graded for blinding as follows.
1. Blinding of clinician (person delivering treatment) to
treatment allocation.
2. Blinding of participant to treatment allocation.
3. Blinding of outcome assessor to treatment allocation.
Follow up
Each study was graded as to whether numbers of and reasons
for drop-outs and withdrawals in all intervention groups were
described, or if it was specified that there were no drop-outs or
withdrawals.
Dealing with missing data
The authors planned to request further information from the pri-
mary investigators where required but as the only included study
was published in 1992, we did not contact the authors (Tamaoki
1992)
Assessment of heterogeneity
We planned to describe any heterogeneity between the study re-
sults and test this to see if it reached statistical significance using
the Chi2 test. We would have considered heterogeneity to be sig-
nificant if the P value was less than 0.10 (Higgins 2008). We also
planned to use the I2 statistic, where heterogeneity is categorised
such that a value of under 25% is considered low, around 50% is
considered moderate and over 75% is considered a high degree of
heterogeneity (Higgins 2003).
Assessment of reporting biases
If meta-analysis had been possible, we would have assessed pub-
lication bias using a funnel plot. We intended to investigate and
report on any selective reporting.
Data synthesis
For the dichotomous outcome variables of each individual study,
we would have calculated the odds ratios (OR) using a modified
intention-to-treat analysis. This analysis assumes that children not
available for outcome assessment have not improved (and prob-
ably represents a conservative estimate of effect). An initial qual-
itative comparison of all the individually analysed studies exam-
ines whether pooling of results (meta-analysis) is reasonable. This
would take into account differences in study populations, inclu-
sion/exclusion criteria, interventions, outcome assessment and es-
timated effect size.
The results from studies that met the inclusion criteria and re-
ported any of the outcomes of interest were to be included in the
subsequent meta-analyses. We planned to calculate the summary
weighted odds ratio and 95%confidence interval (CI) (fixed-effect
model) (Cochrane statistical package, RevMan version 5 (RevMan
2008)). We would only have combined data from parallel studies.
We planned to calculate numbers needed to treat (NNT) from
the pooled OR and its 95% CI applied to a specified baseline
risk using an online calculator (Cates 2003). If studies reported
outcomes using different measurement scales, we planned to es-
timate the standardised mean difference (SMD). We would have
described and explored any heterogeneity between the study re-
sults. We would have included the 95% CI estimated using a ran-
dom-effects model whenever there were concerns about statistical
heterogeneity.
Subgroup analysis and investigation of heterogeneity
The following a priori subgroup analyses were planned:
1. children (aged 18 years or less) and adults (> 18 years);
2. severity of bronchiectasis (based on FEV1: > 80% classified
as mild, 50% to 79% classified as moderate, 30% to 49%
classified as severe, < 30% classified as very severe).
Sensitivity analysis
We also planned sensitivity analyses to assess the impact of the
potentially important factors on the overall outcomes:
• variation in the inclusion criteria;
• differences in the medications used in the intervention and
comparison groups;
• differences in outcome measures;
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• analysis using random-effects model;
• analysis by treatment received; and
• analysis by intention-to-treat.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See the ’Characteristics of included studies’ and ’Characteristics
of excluded studies’ tables.
Results of the search
The Airways Group specialised register/literature search per-
formed in Oct 2008 and October 2009 yielded 173 (153 and
20 respectively) references. There were no RCTs which focused
specifically on adults or children with bronchiectasis. We iden-
tified two publications which were considered for inclusion in
this review. One study Tamaoki 1992 was included; the second
(Llewellyn-Jones 1995) did not meet the eligibility criteria and
was excluded.
Included studies
There were no studies identified which focused solely on
bronchiectasis in either adults or children. However a single, small
study on adults with chronic lung disease, including bronchiecta-
sis, was included in this review as the additional two chronic lung
disease conditions in the study lead to bronchiectasis, and bronch-
orrhoea is a key clinical feature of bronchiectasis. The detail of this
study is described in the ’Characteristics of included studies’ table.
Tamaoki and colleagues (Tamaoki 1992) examined the short-term
effect (14 days) of inhaled indomethacin on sputum and blood in-
dices, dyspnoea scale and lung function in 25 adults with chronic
lung disease (eight with bronchiectasis, 12 with chronic bronchitis
and five with diffuse panbronchiolitis).
Excluded studies
We excluded one study (Llewellyn-Jones 1995) as it was not a
randomised controlled trial.
Risk of bias in included studies
Allocation
The method used for allocating treatment groups was not de-
scribed.
Blinding
The patients and investigators responsible for disease followup and
data analysis were blinded. The doctor responsible for allocating
treatment groups was not blinded but was not involved in follow
up or data analysis.
Incomplete outcome data
Data were complete for all participants. However, data analysis did
not distinguish bronchiectasis patients from the other respiratory
groups, other than that for sputum production.
Selective reporting
We identified no selective reporting bias in the study.
Other potential sources of bias
We identified no other potential sources of bias.
Effects of interventions
The one study included in this review evaluated the effect of in-
haled indomethacin on sputum production, quality of life and
lung function in 25 patients with chronic lung disease, including
eight patients with bronchiectasis.
Respiratory symptoms
The only clinical data reported were in the form of the Borg score,
which showed a significant difference between groups (difference
of -1.90; 95% CI -3.15 to -0.65) (Analysis 1.1). (The minimum
clinically important difference (in COPD) is 1 unit (Ries 2005)).
Days with respiratory symptoms (our primary outcome measure)
was not reported in the study.
Lung function
There was no significant difference between groups for FEV1 %
predicted (difference between groups of -2.90%; 95% CI -13.30
to 7.50) or for vital capacity (VC)%predicted (difference -2.90%;
95% CI -10.58 to 4.78) (Analysis 2.1 and Analysis 2.2).
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Other indices
For sputum indices (Analysis 3.2), a significant decrease in sputum
production in the indomethacin group was found compared with
the placebo group (difference -75.00 g/day; 95% CI -134.61 to -
15.39) but there was no difference in the density of bacteria per
gram of sputum (difference -0.30; 95% CI -1.71 to 1.11).
For blood indices (Analysis 3.3) no significant difference be-
tween groups was found for either erythrocyte sedimentation rate
(ESR) (difference -2.00 mm/hr; 95% CI -13.42 to 9.42) or total
white cell count (difference -400.00 cells/ml; 95% CI -1654.94
to 854.94).
Adverse events
No adverse events were reported in the study.
D I S C U S S I O N
Summary of main results
Data from one small, short-term (14-day) study of 25 adults
with chronic lung disease (12 with chronic bronchitis, eight with
bronchiectasis and five with panbronchiolitis) suggest that inhaled
indomethacin (a type of NSAID) was significantly beneficial in
reducing sputum production and improving dyspnoea compared
to placebo. The clinically important difference for the Borg scale
in bronchiectasis is unknown but that for COPD is 1 unit (Ries
2005) and thus the difference between groups for dyspnoea (-1.90;
95% CI -3.15 to -0.65) is likely to be clinically important.
There was no difference between groups for lung function or blood
indices.
Overall completeness and applicability of
evidence
The small study and limited number of patients with bronchiecta-
sis in the sole included study limits any definitive conclusion. We
included this study on the same basis for inclusion as a study in the
Cochrane Review of pneumococcal vaccination for bronchiectasis
(Chang 2009).
No randomised controlled trials of inhaled NSAIDs in children
with bronchiectasis were identified.
Quality of the evidence
The sole included study in this review (Tamaoki 1992) was a dou-
ble-blind, randomised study but the sample size was small and allo-
cation concealment remains unknown.Data from the three disease
states were described and analysed collectively, thus bronchiecta-
sis-specific data are unknown. Data were expressed as means +/-
SEM (standard error of the mean). Two-way analysis of variance
and Student’s paired t test were used for normally distributed vari-
ables. TheNewman-Keuls test was used formultiple comparisons.
A P value of less than 0.05 was considered statistically significant.
Agreements and disagreements with other
studies or reviews
TheCochraneReviewof oralNSAIDs for cystic fibrosis concluded
that NSAIDs are likely to slow the progression of lung disease
(Lands 2007). Data on sputum production or dyspnoea were not
reported in the review. The Cochrane Review of oral NSAIDs for
bronchiectasis (Kapur 2007) did not find any relevant studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although a single study has shown some benefit in the short-term
use of inhaled indomethacin in adults with chronic lung disease
(including bronchiectasis and those at risk of bronchiectasis), there
is currently insufficient evidence to support or refute the use of in-
haled NSAIDs in children or adults with bronchiectasis. NSAIDs
may be beneficial in the immediate term in reducing sputum pro-
duction and therefore improving quality of life in adults with
chronic lung disease. However, there were too few bronchiectasis
patients included in the study group and the duration of treatment
was too short to provide adequate information on the beneficial or
adverse effects of inhaled NSAIDs in adults with bronchiectasis.
There is no data currently available on the effectiveness of inhaled
NSAIDs in children with bronchiectasis.
Implications for research
The data presented in the one study included in this review indicate
that a double-blind, randomised, placebo-controlled trial is war-
ranted to investigate the short-term (< 12 months) and long-term
(> 12 months) beneficial and adverse effects of inhaled NSAIDs
in both adults and children with bronchiectasis. Randomised con-
trolled trials should investigate children and adults separately and
include data as highlighted in the ’Types of outcome measures’
section of this review.
A C K N OW L E D G E M E N T S
We thank Toby Lasserson, Dr Chris Cates, Elizabeth Arnold and
Susan Ann Hansen from the Airways Group for their advice, sup-
portive role and comments on the protocol and review. We also
7Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
thank Dr Andre Wattiaux from Menzies School of Health Re-
search for translating a French article identified by the literature
search.
R E F E R E N C E S
References to studies included in this review
Tamaoki 1992 {published data only}
Tamaoki J, Chiyotani A, Kobayashi K, Sakai N, Kanemura
T, Takizawa T. Effect of indomethacin on bronchorrhea in
patients with chronic bronchitis, diffuse panbronchiolitis,
or bronchiectasis. American Review of Respiratory Disease
1992;145(3):548–52.
References to studies excluded from this review
Llewellyn-Jones 1995 {published data only}
Llewellyn-Jones CG, Johnson MM, Mitchell JL, Pye A,
Okafor VC, Hill SL, et al.In vivo study of indomethacin
in bronchiectasis: effect on neutrophil function and lung
secretion. European Respiratory Journal 1995;8:1479–87.
Additional references
Behrman 2003
Behrman RE, Kliegman RM, Jenson HB. Nelson Textbook
of Pediatrics. 17th Edition. Philadelphia: Saunders, 2003.
Cates 2003
Cates C. Visual Rx. Online NNT Calculator. http://
www.nntonline.net/: Cates C, 2003.
Chang 2008
Chang AB, Bilton D. Non-cystic fibrosis bronchiectasis
exacerbations. Thorax 2008;63:269–76.
Chang 2009
Chang CC, Singleton RJ, Morris PS, Chang AB.
Pneumococcal vaccines for children and adults with
bronchiectasis. Cochrane Database of Systematic Reviews
2009, Issue 2. [Art. No.: CD006316. DOI: 10.1002/
14651858.CD006316.pub3]
Cole 1986
Cole PJ. Inflammation: a two edged sword. The model of
bronchiectasis. European Journal of Respiratory Disease 1986;
147(Suppl):6–15.
Courtney 2008
Courtney J, Kelly M, Watt A, Garske L, Bradley J, Ennis M,
et al.Quality of life and inflammation in exacerbations of
bronchiectasis. Chronic Respiratory Disease 2008;5:161–8.
Crockett 2001
Crockett AJ, Cranston JM, Latimer KM, Alpers JH.
Mucolytics for bronchiectasis. Cochrane Database of
Systematic Reviews 2001, Issue 1. [Art. No.: CD001289.
DOI: 10.1002/14651858.CD001289]
Cymbala 2005
Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May
JJ, Victory JM, et al.The disease-modifying effects of twice-
weekly oral azithromycin in patients with bronchiectasis.
Treatments in Respiratory Medicine 2005;4:117–22.
Gursel 2006
Gursel G. Does coexistence with bronchiectasis influence
intensive care unit outcome in patients with chronic
obstructive pulmonary disease?. Heart & Lung 2006;35(1):
58–65.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327:
557–60.
Higgins 2008
Higgins JPT, Green S (editors). Available from
www.cochrane-handbook.org. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.0 [updated
February 2008]. The Cochrane Collaboration (available
from www.cochrane-handbook.org) 2008.
Jüni 2001
Jüni P, Altman DG, Egger M. Systematic reviews in health
care: assessing the quality of controlled clinical trials. BMJ
2001;232 (7303):42–6.
Kapur 2007
KapurN, Chang AB.Oral non-steroidal anti-inflammatories
for children and adults with bronchiectasis. Cochrane
Database of Systematic Reviews 2007, Issue 4. [DOI:
10.1002/14651858.CD006427.pub2]
Karadag 2005
Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E.
Non-cystic-fibrosis bronchiectasis in children: a persisting
problem in developing countries. Respiration 2005;72(3):
233–8.
Karakoc 2001
Karakoc GB, Yilmaz M, Altintas DU, Kendirli SG.
Bronchiectasis: still a problem. Pediatric Pulmonology 2001;
32(2):175–8.
Keistinen 1997
Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL.
Bronchiectasis: an orphan disease with a poorly-understood
prognosis. European Respiratory Journal 1997;10(12):
2784–7.
Lands 2007
Lands C, Stanojevic S. Oral non-steroidal anti-inflammatory
drug therapy for cystic fibrosis. Cochrane Database
of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/
14651858.CD001505.pub2]
Lewis 2002
Lewis MM, Mortelliti MP, Yeager H Jr, Tsou E. Clinical
bronchiectasis complicating pulmonary sarcoidosis: case
8Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
series of seven patients. Sarcoidosis, Vasculitis, and Diffuse
Lung Diseases 2002;19(2):154–9.
Martinez-Gracia 2005
Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez
P, Soler-Cataluna JJ. Quality-of-life determinants in patients
with clinically stable bronchiectasis. Chest 2005;128:
739–45.
Mochizuki 2002
Mochizuki H, Ohki Y, Arakawa H, Kato M, Tokuyama K,
Morikawa A. Effect of inhaled indomethacin on distilled
water-induced airway epithelial cell swelling. Journal of
Applied Physiology 2002;92:155–61.
Muthalithas 2008
Mutalithas K, Watkin G, Willig B, Wardlaw A, Pavord
I, Birring SS. Improvement in health status following
bronchopulmonary hygiene physical therapy in patients
with bronchiectasis. Respiratory Medicine 2008;102:
1140–4.
O’Brien 2000
O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological
and radiological characterisation of patients diagnosed with
chronic obstructive pulmonary disease in primary care.
Thorax 2000;55(8):635–42.
Ong 2004
Ong KC, Kor AC, Earnest A, Wang YT. Effects of inhaled
furosemide on exertional dyspnea in chronic obstructive
pulmonary disease. American Journal of Respiratory and
Critical Care Medicine 2004;169:1028–33.
RevMan 2008
The Nordic Cochrane Centre, The Cochrane Collaboraion.
Review Manager (RevMan). 5.0. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboraion, 2008.
Ries 2005
Ries AL. Minimally clinically important difference for the
UCSD Shortness of Breath Questionnaire, Borg Scale, and
visual analog scale. COPD: Journal of Chronic Obstructive
Pulmonary Disease 2005;2:105–10.
Sestini 1999
Sestini P, Refini RM, Pieroni MG, Vaghi A, Robuschi M,
Bianco S. Different effects of inhaled asprinlike drugs on
allergy-induced early and late asthmatic responses. American
Journal of Respiratory and Critical Care Medicine 1999;159:
1228–33.
∗ Indicates the major publication for the study
9Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Tamaoki 1992
Methods Double-blind, randomised, placebo-controlled trial
Pulmonary function was assessed by a change in vital capacity (VC) and FEV1 pre-treatment (day 0)
and on day 14. Quality of life was assessed by Borg’s ratio scale to questions related to breathlessness
and dyspnoea
Sputum was analysed for change in production (g/day), cyclooxygenase products (PGE2, PGF2a ,
6-oxo-PGF1a , TxB2) and microbiological culture
Statistical analysis: data were expressed as means +/- SEM. Two-way analysis of variance and Stu-
dent’s paired t test were used for normally distributed variables. The Newman-Keuls test was used
for multiple comparisons. A P value of less than 0.05 was considered statistically significant
Participants 25 adults (age 29 to 78 years) diagnosed with chronic lung disease (chronic bronchitis, diffuse pan-
bronchiolitis or bronchiectasis) and bronchorrhoea of at least 4 weeks. Eight of the 25 participants
had bronchiectasis but all had symptoms of bronchiectasis and 21 had chronic colonisation with
respiratory pathogens present in adults with bronchiectasis - 17 had Pseudomonas aeruginosa, 3 with
Haemophilus influenzae and one with Staphylococcus aureus. Of the 8 subjects with bronchiectasis,
4 were allocated to the indomethacin group and 4 to the placebo group. All had no history of
respiratory allergy
Interventions Treatment group 1: inhaled indomethacin, 2 ml aerosol preparation of 1.2 µg/ml in saline 3 times
daily for 14 days
Treatment group 2: inhaled placebo, 2 ml aerosolised saline alone 3 times daily for 14 days
Method of delivery: nebuliser delivering aerosolised particles with a median particle diameter of 4.
5 to 5 µm
Outcomes Data for all 3 disease states were analysed collectively. Outcomes were sputum indices (% solid
composition, sputum bacterial density and inflammatory markers - prostaglandin E2, PGF2a , 6-
oxo-PGF1a , TxB2), Borg score ratio scale for breathlessness and dyspnoea, white cell count (WCC)
, erythrocyte sedimentation rate (ESR) and spirometry
The only outcome for which results were reported separately for bronchiectasis patients was effect
on sputum production
Notes We elected to include all outcomes as although not all had the diagnosis of bronchiectasis, the
additional 2 diseases (chronic bronchitis and panbronchiolitis) overlap with bronchiectasis and can
eventually lead to bronchiectasis. Furthermore, the high number colonised with bacteria especially
with Pseudomonas indicates that bronchiectasis would have been likely to be present if a multi-
detector high resolution CT scan was performed in all subjects
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described
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Tamaoki 1992 (Continued)
Allocation concealment? Unclear The authors state that the study is a double-
blind, randomised, placebo-controlled trial but
do not describe the randomisation process, in-
cluding allocation concealment
Blinding?
Sputum volume
Yes The patients and investigators responsible for
disease follow up and data analysis were blinded.
The doctor responsible for allocating treatment
groups was not blinded but was not involved in
follow up or data analysis
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Llewellyn-Jones 1995 Study using oral indomethacin
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D A T A A N D A N A L Y S E S
Comparison 1. Clinical symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Borg score 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Comparison 2. Lung function
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1% predicted (end of study) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 VC % predicted (end of study) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Comparison 3. Other indices
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Wet weight of sputum at end of
study (g/day)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Bacterial load of sputum at end
of study (Log10 cfu/g)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 White cell count at end of study
(per mm3)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 ESR at end of study (mm/h) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Clinical symptoms, Outcome 1 Borg score.
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 1 Clinical symptoms
Outcome: 1 Borg score
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 4.5 (1.44) 12 6.4 (1.73) -1.90 [ -3.15, -0.65 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours indomethacin Favours placebo
Analysis 2.1. Comparison 2 Lung function, Outcome 1 FEV1 % predicted (end of study).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 2 Lung function
Outcome: 1 FEV1 % predicted (end of study)
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 72.7 (12.98) 12 75.6 (13.51) -2.90 [ -13.30, 7.50 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours indomethacin Favours placebo
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Analysis 2.2. Comparison 2 Lung function, Outcome 2 VC % predicted (end of study).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 2 Lung function
Outcome: 2 VC % predicted (end of study)
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 82.6 (8.65) 12 85.5 (10.74) -2.90 [ -10.58, 4.78 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours indomethacin Favours placebo
Analysis 3.1. Comparison 3 Other indices, Outcome 1 Wet weight of sputum at end of study (g/day).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 3 Other indices
Outcome: 1 Wet weight of sputum at end of study (g/day)
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 95 (75.72) 12 170 (76.21) -75.00 [ -134.61, -15.39 ]
-100 -50 0 50 100
Favours Indomethacin Favours placebo
14Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.2. Comparison 3 Other indices, Outcome 2 Bacterial load of sputum at end of study (Log10
cfu/g).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 3 Other indices
Outcome: 2 Bacterial load of sputum at end of study (Log10 cfu/g)
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 7.8 (2.16) 12 8.1 (1.39) -0.30 [ -1.71, 1.11 ]
-4 -2 0 2 4
Favours indomethacin Favours placebo
Analysis 3.3. Comparison 3 Other indices, Outcome 3 White cell count at end of study (per mm3).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 3 Other indices
Outcome: 3 White cell count at end of study (per mm3)
Study or subgroup Indomethcin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 6500 (1442) 12 6900 (1732.1) -400.00 [ -1654.94, 854.94 ]
-500 -250 0 250 500
Favours experimental Favours control
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Analysis 3.4. Comparison 3 Other indices, Outcome 4 ESR at end of study (mm/h).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 3 Other indices
Outcome: 4 ESR at end of study (mm/h)
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 22 (10.8) 12 24 (17.32) -2.00 [ -13.42, 9.42 ]
-100 -50 0 50 100
Favours Indomethacin Favours placebo
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